RayKnowChina Research Map
Shortlist0

Capital Medical University

首都医科大学

BeijingUniversity or health system

Hospitals that carry this university's name, added together, plus papers and trials that name only the university.

Research activity, not treatment quality. Not medical advice. How this works

Nasopharyngeal carcinoma

鼻咽癌
0.5%Leads under 1 in 100 of China's research papers on NPC

Led 13 of 2,375 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (23.4%).

Run this PubMed search

Open trials led
0
Research papers it led
13
Trials it led
2
Share of China's trials
0.3%
Share of the world's papers
0.4%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 332025
ThemesRecurrent / metastatic diseaseRadiotherapy techniqueInduction / concurrent chemotherapy

Hospitals counted here

  1. Beijing Tongren Hospital6
  2. Beijing Tiantan Hospital Counted in the group total2
  3. Beijing Anzhen Hospital Counted in the group total2
  4. Xuanwu Hospital Counted in the group total1
  5. Beijing Shijitan Hospital Counted in the group total1
  6. Xuan Wu Hospital, Capital Medical University Counted in the group total1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Oesophageal squamous cell carcinoma

食管鳞状细胞癌
1.1%Leads about 1 in 92 of China's research papers on ESCC ▼ from 1.8%

Led 32 of 2,923 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (6.9%).

Run this PubMed search

Open trials led
0
Research papers it led
32
Trials it led
1
Share of China's trials
0.2%
Share of the world's papers
0.7%
Papers led per year
2021: 2220212022: 0020222023: 1120232024: 0020242025: 222025
ThemesMolecular markers & genomicsImmunotherapyEarly detection & endoscopy

Over half of these papers are lab or animal studies.

Hospitals counted here

  1. Beijing Friendship Hospital12
  2. Beijing Chao-Yang Hospital8
  3. Beijing Anzhen Hospital6
  4. Beijing Tiantan Hospital Counted in the group total1
  5. Beijing Jishuitan Hospital Counted in the group total1
  6. Beijing Tongren Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Predicting pathological response of resectable esophageal squamous cell carcinoma to neoadjuvant anti-PD-1 with chemotherapy using serum inflammation indexes.2025Scientific reportsFree full text
  2. p53 and Ki-67 combined with periodic acid-Schiff staining for the diagnosis of early stage esophageal squamous cell carcinoma lesions in biopsy specimens.2025Esophagus : official journal of the Japan Esophageal SocietyFree full text
  3. Endoscopic Submucosal Dissection for Hypervascularized Esophageal Squamous Cell Carcinoma in Decompensated Cirrhosis With Esophageal Varices and Scars.2023The American journal of gastroenterologyFree full text
  4. Comorbid early esophageal cancer and Gongylonema pulchrum infection: a case report.2021BMC gastroenterologyFree full text
  5. Immune checkpoint inhibitor-related pneumonitis induced by camrelizumab: a case report and review of literature.2021Annals of palliative medicine
Trials on ClinicalTrials.gov6
  1. A Study of PF-08046054/SGN-PDL1V in Advanced Solid TumorsRecruitingNCT05208762Study sitePhase 1Start 2022-10
  2. Chemoprevention of Esophageal Squamous Cell Carcinoma (ESCC) With Aspirin and Tea PolyphenolsStatus unknownNCT01496521Lead sponsorPhase 3Start 2012-01
  3. Study To Investigate the Efficacy and Safety of Sitravatinib in Combination With Tislelizumab in Participants With Esophageal Squamous Cell CarcinomaTerminatedNCT05461794Study sitePhase 2Start 2022-10
  4. Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Recurrent or Metastatic Esophageal Squamous Cell CarcinomaCompletedNCT04732494Study sitePhase 2Start 2021-03
  5. A Study of Atezolizumab Plus Tiragolumab in Combination With Paclitaxel and Cisplatin Compared With Paclitaxel and Cisplatin as First-Line Treatment in Participants With Unresectable Locally Advanced, Unresectable Recurrent, or Metastatic Esophageal CarcinomaCompletedNCT04540211Study sitePhase 3Start 2020-10
  6. Performance of White Light, NBI and Iodine Staining Endoscopy in the Diagnosis of Esophageal LesionsStatus unknownNCT04170257Study siteN/AStart 2019-10

PubMed searchClinicalTrials.gov

Hepatocellular carcinoma

肝细胞癌
2.0%Leads about 1 in 51 of China's research papers on HCC

Led 290 of 14,765 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (5.5%).

Run this PubMed search

Open trials led
1
Research papers it led
290
Trials it led
14
Share of China's trials
1.0%
Share of the world's papers
1.0%
Papers led per year
2021: 0020212022: 1120222023: 1120232024: 1120242025: 222025
ThemesRecurrence & prognosisImaging, AI & early detectionLocal treatment (ablation, TACE, HAIC)
Papers it led5
  1. Impact of temporary atezolizumab and bevacizumab interruption on survival in advanced HCC: an IMbrave150 analysis.2025The oncologistRCTFree full text
  2. Efficacy and Safety of Fuzheng Jiedu Xiaoji Formula Combined with Conventional Western Therapy in Advanced HBV-HCC: A Single-Center, Randomized Controlled Trial.2025Chinese journal of integrative medicineRCT
  3. Efficacy of CalliSpheres® drug-loaded microspheres combined with doxorubicin in hepatocellular carcinoma.2024Scandinavian journal of gastroenterologyRCT
  4. Diagnosis of primary clear cell carcinoma of the liver based on Faster region-based convolutional neural network.2023Chinese medical journalRCTFree full text
  5. Predictive value of hepatic venous pressure gradient and efficacy and significance of early PTVE for gastrointestinal bleeding after TACE for liver cancer.2022Journal of cancer research and therapeuticsRCT
Trials on ClinicalTrials.gov6
  1. HCC Risk Prediction Model Based on Multimodal Data in Chronic Hepatitis BNot yet recruitingNCT07780357Lead sponsorStart 2026-08
  2. A Phase Ib/II Trial to Evaluate the Efficacy and Safety of HH-009 for the Treatment of FGF19-positive Advanced or Unresectable HCCRecruitingNCT07547553Study sitePhase 1/Phase 2Start 2026-05
  3. InstaSure™ Non-Invasive Finger-Press Test for Hepatocellular CarcinomaRecruitingNCT07848750Study siteStart 2026-06
  4. MRG006A Combination Therapy for Advanced Hepatocellular Carcinoma (Phase I/II)RecruitingNCT07479485Study sitePhase 1/Phase 2Start 2026-04
  5. NWRD06 DNA Plasmid for HCC After Curative Resection.RecruitingNCT07324304Study sitePhase 2Start 2025-12
  6. Computer-Aided Diagnosis for Hepatocellular Carcinoma Microvascular InvasionRecruitingNCT07170345Study siteStart 2025-09

PubMed searchClinicalTrials.gov

Stomach cancer

胃癌
1.2%Leads about 1 in 86 of China's research papers on Stomach cancer

Led 113 of 9,782 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (3.9%).

Run this PubMed search

Open trials led
7
Research papers it led
113
Trials it led
18
Share of China's trials
1.2%
Share of the world's papers
0.5%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 442025
ThemesImaging & AIEarly detection & endoscopyPeritoneal spread & advanced disease

Hospitals counted here

  1. Beijing Friendship Hospital45
  2. Beijing Tongren Hospital15
  3. Beijing Shijitan Hospital14
  4. Beijing Chao-Yang Hospital12
  5. Xuanwu Hospital5
  6. Beijing Hospital, Capital Medical University Counted in the group total5

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Alpha-enolase influences ATP pool of cytoplasm and lactate homeostasis by regulating glycolysis in gastric cancer.2025Signal transduction and targeted therapyFree full text
  2. Comparison on the reflux and nutritional status of different reconstruction methods after laparoscopic proximal gastrectomy: a systematic review and network meta-analysis.2026Updates in surgeryFree full text
  3. Diagnostic Value of Joint Detection of Serum TK1, TSGF, CA199, and CA724 for Gastric Cancer and Its Relationship With Clinicopathologic Features and Prognosis.2025The American surgeon
  4. Development and validation of a nomogram incorporating dietary factors for predicting Helicobacter pylori-negative early gastric cancer risk.2025World journal of gastroenterologyFree full text
  5. Prognostic significance of lymph node ratio in adenocarcinoma of the esophagogastric junction: a study of patients after radical gastrectomy.2025World journal of surgical oncologyFree full text
Trials on ClinicalTrials.gov6
  1. Retrospective Analysis of Early Gastric Cancer Patients Based on Prospective Clinical DatasetRecruitingNCT07747688Lead sponsorStart 2026-05
  2. Image-Guided Platform-Assisted Sentinel Lymph Node Retrieval in Early Gastric CancerRecruitingNCT07835087Lead sponsorN/AStart 2026-08
  3. Digital Rehabilitation for Gastric Cancer Surgery After Neoadjuvant TherapyRecruitingNCT07441850Lead sponsorN/AStart 2026-03
  4. Iparomlimab and Tuvonralimab (QL1706) Combined With Chemotherapy for Previously Untreated Advanced or Metastatic Gastric or Gastroesophageal Junction CancerRecruitingNCT07315854Lead sponsorPhase 2Start 2025-11
  5. Adebrelimab Plus Apatinib Combined With SOX Regimen as Conversion Therapy for Gastric CancerRecruitingNCT07353684Lead sponsorPhase 2Start 2025-05
  6. Fluorescence Guided Laparoscopic-Endoscopic Cooperative Sentinel Lymph Node Navigation Surgery Strategy for Early Gastric Cancer(IDEAL Stage 2b)RecruitingNCT06788548Lead sponsorN/AStart 2024-02

PubMed searchClinicalTrials.gov

Hepatoblastoma

肝母细胞瘤
9.1%Leads about 1 in 11 of China's research papers on Hepatoblastoma ▲ from 5.9%

Led 14 of 154 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (13.6%).

Run this PubMed search

Open trials led
0
Research papers it led
14
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
3.1%
Papers led per year
2021: 0020212022: 0020222023: 4420232024: 0020242025: 112025

Hospitals counted here

  1. Beijing Tongren Hospital8
  2. Beijing Children's Hospital4
  3. Beijing Friendship Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Retinoblastoma

视网膜母细胞瘤
9.3%Leads about 1 in 11 of China's research papers on Retinoblastoma

Led 28 of 301 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (12.0%).

Run this PubMed search

Open trials led
0
Research papers it led
28
Trials it led
1
Share of China's trials
7.7%
Share of the world's papers
2.5%
Papers led per year
2021: 0020212022: 0020222023: 2220232024: 2220242025: 112025

Hospitals counted here

  1. Beijing Tongren Hospital21
  2. Beijing Children's Hospital6
  3. Beijing Friendship Hospital1
  4. Beijing Luhe Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Chordoma

脊索瘤
23.8%Leads about 1 in 4 of China's research papers on Chordoma

Led 25 of 105 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (23.8%).

Run this PubMed search

Open trials led
0
Research papers it led
25
Trials it led
3
Share of China's trials
50.0%
Share of the world's papers
4.5%
Papers led per year
2021: 0020212022: 1120222023: 1120232024: 2220242025: 112025

Over half of these papers are lab or animal studies.

Hospitals counted here

  1. Beijing Tiantan Hospital14
  2. Xuanwu Hospital7
  3. Sanbo Brain Hospital2
  4. Beijing Chao-Yang Hospital2

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Osteosarcoma

骨肉瘤
1.6%Leads about 1 in 65 of China's research papers on Osteosarcoma

Led 35 of 2,257 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (4.3%).

Run this PubMed search

Open trials led
0
Research papers it led
35
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.7%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 2220242025: 332025

PubMed searchClinicalTrials.gov

Gastrointestinal stromal tumour

胃肠道间质瘤
1.0%Leads under 1 in 100 of China's research papers on Gastrointestinal stromal tumour

Led 5 of 523 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (6.3%).

Run this PubMed search

Open trials led
0
Research papers it led
5
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.3%
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 1120242025: 332025

Hospitals counted here

  1. Beijing Hospital, Capital Medical University2
  2. Beijing Friendship Hospital2
  3. Capital Medical University Electric Teaching Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Neuroblastoma

神经母细胞瘤
8.8%Leads about 1 in 11 of China's research papers on Neuroblastoma ▲ from 4.7%

Led 100 of 1,132 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (8.8%).

Run this PubMed search

Open trials led
1
Research papers it led
100
Trials it led
1
Share of China's trials
2.4%
Share of the world's papers
2.3%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 2220242025: 002025

Hospitals counted here

  1. Beijing Friendship Hospital47
  2. Beijing Children's Hospital33
  3. Beijing Tongren Hospital9
  4. Xuanwu Hospital3
  5. Fuxing Hospital2
  6. Beijing Luhe Hospital2

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Ewing sarcoma

尤文肉瘤
4.9%Leads about 1 in 20 of China's research papers on Ewing sarcoma ▲ from 2.4%

Led 8 of 163 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (8.6%).

Run this PubMed search

Open trials led
0
Research papers it led
8
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.7%
Papers led per year
2021: 0020212022: 0020222023: 2220232024: 3320242025: 002025

Hospitals counted here

  1. Beijing Children's Hospital4
  2. Beijing Chao-Yang Hospital2
  3. Beijing Friendship Hospital1
  4. Beijing Tongren Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Multiple myeloma

多发性骨髓瘤
3.9%Leads about 1 in 25 of China's research papers on Myeloma

Led 66 of 1,676 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (4.8%).

Run this PubMed search

Open trials led
0
Research papers it led
66
Trials it led
4
Share of China's trials
0.8%
Share of the world's papers
0.7%
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 1120242025: 222025
ThemesDiagnosis, MRD & riskDrug combinationsStem cell transplant

Hospitals counted here

  1. Beijing Chao-Yang Hospital52
  2. Beijing Tongren Hospital6
  3. Xuanwu Hospital Counted in the group total2
  4. Beijing Jishuitan Hospital2
  5. Beijing Friendship Hospital1
  6. Beijing Tiantan Hospital Counted in the group total1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Aponermin or placebo in combination with thalidomide and dexamethasone in the treatment of relapsed or refractory multiple myeloma (CPT-MM301): a randomised, double-blinded, placebo-controlled, phase 3 trial.2023BMC cancerRCTFree full text
  2. Comparison of CAR T-cell and bispecific antibody as third-line or later-line treatments for multiple myeloma: a meta-analysis.2024Journal for immunotherapy of cancerFree full text
  3. Prognostic Implications of Measurable Residual Disease and Autologous Hematopoietic Stem Cell Transplantation in Primary Plasma Cell Leukemia in the Era of Novel Agents.2026Transplantation and cellular therapy
  4. Temporal trends and disparities in cardiovascular disease-related mortality among adults with multiple myeloma in the United States, 1999-2023.2025BMC cardiovascular disordersFree full text
  5. Pretreatment hemoglobin, myeloma subtype, and induction regimens as independent prognostic factors for survival after autologous stem cell transplantation in multiple myeloma: a retrospective cohort study.2025Hematology (Amsterdam, Netherlands)
Trials on ClinicalTrials.gov6
  1. Study of YKST02 in Adults With Relapsed or Refractory Multiple MyelomaNot yet recruitingNCT07695740Study sitePhase 2Start 2027-12
  2. A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple MyelomaRecruitingNCT07518186Study sitePhase 3Start 2026-05
  3. Study to Assess Safety and Efficacy of HDP-101 in Chinese Patients With Relapsed or Refractory Multiple MyelomaRecruitingNCT07529782Study sitePhase 1Start 2026-03
  4. Safety and Efficacy of KSVCBD Injection in Multiple Myeloma Expressing CD19 and/or BCMARecruitingNCT07620275Study sitePhase 1Start 2026-09
  5. Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple MyelomaNot yet recruitingNCT07569757Study sitePhase 3Start 2026-06
  6. A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple MyelomaRecruitingNCT07477587Study sitePhase 1Start 2026-05

PubMed searchClinicalTrials.gov

B-cell acute lymphoblastic leukaemia (B-ALL)

B 细胞急性淋巴细胞白血病
2.2%Leads about 1 in 45 of China's research papers on B-ALL ▼ from 4.9%

Led 5 of 225 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (8.9%).

Run this PubMed search

Open trials led
1
Research papers it led
5
Trials it led
2
Share of China's trials
0.8%
Share of the world's papers
0.5%
Papers led per year
2021: 2220212022: 0020222023: 1120232024: 0020242025: 112025
ThemesChildrenPhiladelphia chromosome & geneticsCAR-T & cell therapy

Hospitals counted here

  1. Beijing Children's Hospital4
  2. Beijing Friendship Hospital Counted in the group total1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Baseline [18F]FDG PET/CT characterization of extramedullary disease and prognostic value in relapsed/refractory B-cell acute lymphoblastic leukemia treated with CAR-T cells.2026European journal of nuclear medicine and molecular imaging
  2. A case series of B-Lymphoblastic lymphoma with C-MYC rearrangement in children: diagnostic and therapeutic challenges.2025Annals of hematologyFree full text
  3. Clinical, biological, and outcome features of P2RY8-CRLF2 and CRLF2 over-expression in pediatric B-cell precursor acute lymphoblastic leukemia according to the CCLG-ALL 2008 and 2018 protocol.2023European journal of haematology
  4. Characteristics of Central Nervous System (CNS) Involvement in Children With Non-Hodgkin's Lymphoma (NHL) and the Diagnostic Value of CSF Flow Cytometry in CNS Positive Disease.2021Technology in cancer research & treatmentFree full text
  5. Combined analysis of IKZF1 deletions and CRLF2 expression on prognostic impact in pediatric B-cell precursor acute lymphoblastic leukemia.2021Leukemia & lymphoma
Trials on ClinicalTrials.gov4
  1. CD19/CD22 Bispecific CAR-T Cell Therapy for Relapsed/Refractory B-cell Lymphoma or Acute Lymphoblastic LeukemiaRecruitingNCT06081478Lead sponsorPhase 2Start 2022-01
  2. A Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and AdolescentsRecruitingNCT05334823Study sitePhase 2Start 2022-01
  3. CD19 hsCAR-T for Refractory/Relapsed CD19+ B-ALL PatientsStatus unknownNCT03902197Lead sponsorPhase 2Start 2019-04
  4. A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALLActive, not recruitingNCT04521231Study sitePhase 1/Phase 2Start 2021-01

PubMed searchClinicalTrials.gov

Aplastic anaemia

再生障碍性贫血
2.9%Leads about 1 in 34 of China's research papers on Aplastic anaemia ▲ from 2.1%

Led 12 of 412 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (17.2%).

Run this PubMed search

Open trials led
0
Research papers it led
12
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.8%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 552025
ThemesChildrenStem cell transplantImmunosuppressive treatment

Hospitals counted here

  1. Beijing Children's Hospital9
  2. Beijing Tiantan Hospital Counted in the group total1
  3. Gynecology Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Haemophagocytic lymphohistiocytosis (HLH)

噬血细胞性淋巴组织细胞增生症
22.3%Leads about 1 in 4 of China's research papers on HLH

Led 89 of 399 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (22.3%).

Run this PubMed search

Open trials led
5
Research papers it led
89
Trials it led
27
Share of China's trials
56.2%
Share of the world's papers
5.5%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 332025
ThemesTreatment regimensChildrenDiagnosis & prognosis

Hospitals counted here

  1. Beijing Friendship Hospital52
  2. Beijing Children's Hospital31
  3. Beijing Youan Hospital, Capital Medical University2
  4. Beijing Anzhen Hospital2
  5. Xuanwu Hospital Counted in the group total1
  6. Beijing Tongren Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Prognostic scoring system for pediatric Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis based on baseline characteristics: A multicenter retrospective study.2024Pediatric blood & cancerRCT
  2. Long-Term Outcomes of a Stratified Treatment Regimen Based on Etoposide and Glucocorticoids in Children With Hemophagocytic Lymphohistiocytosis (CCHG-HLH-2018): A Multicenter, Single-Arm Clinical Study.2026American journal of hematology
  3. Characteristics of epilepsy associated with hemophagocytic lymphohistiocytosis.2025Seizure
  4. Monocyte/macrophages may exert prominent roles in macrophage activation syndrome.2025Annals of hematologyFree full text
  5. Case Report: Longitudinal mass cytometry profiling of a patient with disseminated histoplasmosis and secondary hemophagocytic lymphohistiocytosis.2025Frontiers in immunologyFree full text
Trials on ClinicalTrials.gov6
  1. Combination of Mitoxantrone Liposome and Etoposide, Dexamethasone, Pegaspargase and Golidocitinib (MEPL-G) in the Treatment of NK/T-cell Lymphoma Associated Hemophagocytic Lymphohistiocytosis (NKTCL-HLH)RecruitingNCT07525466Lead sponsorPhase 1/Phase 2Start 2026-04
  2. Letermovir Prophylaxis in Children With EBV-Positive T/NK-Cell Lymphoproliferative Disease and Refractory/Relapsed EBV-Associated Hemophagocytic LymphohistiocytosisRecruitingNCT07488728Lead sponsorN/AStart 2025-10
  3. Prospective Single-Arm Clinical Trial of GO Regimen for HLH.RecruitingNCT07339345Lead sponsorPhase 2/Phase 3Start 2025-06
  4. Efficacy and Safety of Carrimycin Tablets in HLH Patients With Carbapenem-resistant InfectionsNot yet recruitingNCT05988177Lead sponsorN/AStart 2023-08
  5. Segmental Resection Combined With DEP Regimen for EBV-HLH Patients With Intestinal InvolvementNot yet recruitingNCT06131489Lead sponsorStart 2023-12
  6. A Phase III Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of Plonmarlimab in Subjects With Relapsed/Refractory Rheumatic and Immunologic Disease-associated Haemophagocytic Lymphohistiocytosis (Also Known as Macrophage Activation Syndrome [MAS])RecruitingNCT07208058Study sitePhase 3Start 2025-11

PubMed searchClinicalTrials.gov

Beta thalassaemia

β 地中海贫血
0.6%Leads under 1 in 100 of China's research papers on Beta thalassaemia

Led 2 of 312 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (9.9%).

Run this PubMed search

Open trials led
0
Research papers it led
2
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.1%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 112025

Hospitals counted here

  1. Xuanwu Hospital1
  2. Beijing Children's Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Haemophilia A

血友病 A
12.9%Leads about 1 in 8 of China's research papers on Haemophilia A ▲ from 8.1%

Led 35 of 272 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (15.8%).

Run this PubMed search

Open trials led
0
Research papers it led
35
Trials it led
2
Share of China's trials
2.4%
Share of the world's papers
1.2%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 3320242025: 222025

Hospitals counted here

  1. Beijing Children's Hospital32
  2. Beijing Tiantan Hospital1
  3. Children's Hospital, Capital Medical University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. The efficacy, safety, and pharmacokinetics of N8-GP in previously treated Chinese patients with haemophilia A: results from the phase 3b pathfinder10 study.2025Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis
  2. Outcomes of immune tolerance induction with rituximab to eradicate high-titer inhibitor of hemophilia A: depicted by exponential decay model and the gene expression profile of different outcomes by RNA-sequencing.2025Journal of thrombosis and haemostasis : JTH
  3. Cost-effectiveness Analysis of Prophylaxis Versus On-demand Treatment for Children With Moderate or Severe Hemophilia A in China.2024Clinical therapeutics
  4. A long term outcomes analysis of severe haemophilia A boys receiving 4 years prophylaxis on the Chinese Haemophilia Individualized escalating low dose Prophylaxis (CHIPS).2024Thrombosis research
  5. Surgical procedures and complications in placement of totally implantable venous access port in pediatric hemophilia patients: A retrospective analysis.2024Blood cells, molecules & diseases
Trials on ClinicalTrials.gov6
  1. Longitudinal Cohort of Thrombosis and Hemostasis DiseasesRecruitingNCT06727669Study siteStart 2024-11
  2. Efficacy and Safety Evaluation Study of SCT800 in Previously Untreated Hemophilia A Patients.RecruitingNCT07437404Study sitePhase 3Start 2024-04
  3. A Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia BRecruitingNCT05611801Study sitePhase 3Start 2022-12
  4. Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without InhibitorsRecruitingNCT05145127Study sitePhase 3Start 2021-11
  5. Low-dose ITI Strategy for Children in Hemophilia A With High-titer Inhibitor and Poor ITI Risk in ChinaStatus unknownNCT03598725Lead sponsorPhase 4Start 2016-01
  6. A Clinical Phenotype Based Individualized Prophylaxis in Chinese Hemophilia A ChildrenStatus unknownNCT02999308Lead sponsorPhase 4Start 2016-08

PubMed searchClinicalTrials.gov

Atypical haemolytic uraemic syndrome

非典型溶血性尿毒症综合征
7.4%Leads about 1 in 13 of China's research papers on Atypical haemolytic uraemic syndrome ▼ from 15.4%

Led 2 of 27 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (11.1%).

Run this PubMed search

Open trials led
0
Research papers it led
2
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.5%
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 0020242025: 112025

Hospitals counted here

  1. Beijing Children's Hospital2

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Thrombotic thrombocytopenic purpura

血栓性血小板减少性紫癜
1.6%Leads about 1 in 64 of China's research papers on Thrombotic thrombocytopenic purpura ▼ from 4.3%

Led 1 of 64 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (9.4%).

Run this PubMed search

Open trials led
0
Research papers it led
1
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.1%
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

Hospitals counted here

  1. Xuanwu Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led1
  1. Complete recovery of deep venous thrombosis from Coombs (+) thrombotic thrombocytopenic purpura: case report.2022Journal of cardiothoracic surgery
Trials on ClinicalTrials.gov2
  1. Longitudinal Cohort of Thrombosis and Hemostasis DiseasesRecruitingNCT06727669Study siteStart 2024-11
  2. A Study of TAK-755 in Participants With Congenital Thrombotic Thrombocytopenic PurpuraActive, not recruitingNCT04683003Study sitePhase 3Start 2021-04

PubMed searchClinicalTrials.gov

Fanconi anaemia

范可尼贫血
2.9%Leads about 1 in 34 of China's research papers on Fanconi anaemia New since 2021

Led 2 of 68 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (8.8%).

Run this PubMed search

Open trials led
0
Research papers it led
2
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.5%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 222025

Hospitals counted here

  1. Beijing Children's Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Neuromyelitis optica spectrum disorder (NMOSD)

视神经脊髓炎谱系疾病
10.5%Leads about 1 in 10 of China's research papers on NMOSD

Led 51 of 485 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (10.5%).

Run this PubMed search

Open trials led
4
Research papers it led
51
Trials it led
12
Share of China's trials
15.4%
Share of the world's papers
2.7%
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 1120242025: 222025
ThemesAntibodies & diagnosisImagingAcute attack treatment

Hospitals counted here

  1. Beijing Tiantan Hospital34
  2. Beijing Tongren Hospital7
  3. Xuanwu Hospital5
  4. Beijing Children's Hospital2
  5. Beijing Anding Hospital Counted in the group total1
  6. Beijing Chao-Yang Hospital Counted in the group total1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Distinct virtual histology of grey matter atrophy in four neuroinflammatory diseases.2024Brain : a journal of neurology
  2. B-Cell Compartmental Features and Molecular Basis for Therapy in Autoimmune Disease.2021Neurology(R) neuroimmunology & neuroinflammationFree full text
  3. Serum GPR37 as a novel biomarker for disease activity, disability, and differential diagnosis in NMOSD.2026Clinica chimica acta; international journal of clinical chemistry
  4. Diagnostic biomarkers for differentiating AQP4-IgG- negative NMOSD from other nervous system autoimmune disorders: a retrospective study.2025Frontiers in immunologyFree full text
  5. Spatiotemporal subtypes of brain and spinal cord atrophy in neuromyelitis optica spectrum disorders and multiple sclerosis.2025BMC medicineFree full text
Trials on ClinicalTrials.gov6
  1. A Multicenter Prospective Real-World Effectiveness and Safety of Satralizumab in the Early Treatment of Attacks in NMOSDRecruitingNCT07762872Lead sponsorStart 2026-07
  2. Universal CAR-T Cells in Patients with Refractory Autoimmune Diseases of the Nervous System.Not yet recruitingNCT06485232Lead sponsorEarly phase 1Start 2025-02
  3. Normal Chinese Lifespan Brain Charts Initiative (NCLBCI)Enrolling by invitationNCT06643858Lead sponsorStart 2023-12
  4. Clinical and Imaging Cohort of Neuroinflammation Diseases in China (CLUE)RecruitingNCT04106830Lead sponsorStart 2019-01
  5. Crisugabalin in NMOSD Neuropathic Pain: A Randomized, Double-Blind, Placebo-Controlled Exploratory TrialNot yet recruitingNCT07699770Study sitePhase 4Start 2026-06
  6. A Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD)RecruitingNCT06413654Study sitePhase 2/Phase 3Start 2024-07

PubMed searchClinicalTrials.gov

IgG4-related disease

IgG4相关性疾病
7.3%Leads about 1 in 14 of China's research papers on IgG4-RD ▲ from 4.9%

Led 18 of 246 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (19.1%).

Run this PubMed search

Open trials led
0
Research papers it led
18
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
1.5%
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 442025
ThemesHead, eye socket & salivary glandsTreatment & relapseDiagnosis & look-alikes

Hospitals counted here

  1. Beijing Friendship Hospital12
  2. Beijing Tongren Hospital3
  3. Xuanwu Hospital2
  4. Beijing Tiantan Hospital Counted in the group total1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Myasthenia gravis

重症肌无力
5.2%Leads about 1 in 19 of China's research papers on Myasthenia gravis

Led 26 of 499 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (6.6%).

Run this PubMed search

Open trials led
1
Research papers it led
26
Trials it led
5
Share of China's trials
5.4%
Share of the world's papers
1.1%
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 442025
ThemesStandard immunotherapyThymus & thymectomyBiologic & complement drugs

Hospitals counted here

  1. Xuanwu Hospital16
  2. Beijing Tongren Hospital6
  3. Beijing Hospital, Capital Medical University Counted in the group total1
  4. Beijing Tiantan Hospital1
  5. Beijing Friendship Hospital1
  6. Beijing Chest Hospital Counted in the group total1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Sugammadex versus Neostigmine Reversal After Thoracoscopic Thymectomy in Myasthenia Gravis: A Multicenter, Randomized Controlled Trial.2025Drug design, development and therapyRCTFree full text
  2. A Randomized Open-Labeled Trial of Methotrexate as a Steroid-Sparing Agent for Patients With Generalized Myasthenia Gravis.2022Frontiers in immunologyRCTFree full text
  3. Dynamic Changes in Peripheral Immune Cells During Efgartigimod Treatment in Naive Generalized Myasthenia Gravis.2025CNS neuroscience & therapeuticsFree full text
  4. Factors associated with early response to efgartigimod in patients with generalized myasthenia gravis: a multicenter retrospective observational study.2025Journal of neurologyFree full text
  5. Gut microbial profiles of patients with optic neuritis or myasthenia gravis.2025The Journal of international medical researchFree full text
Trials on ClinicalTrials.gov6
  1. Universal CAR-T Cells in Patients with Refractory Autoimmune Diseases of the Nervous System.Not yet recruitingNCT06485232Lead sponsorEarly phase 1Start 2025-02
  2. Myasthenia Gravis Registry in ChinaRecruitingNCT06241521Study siteStart 2024-02
  3. Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)RecruitingNCT06463587Study sitePhase 3Start 2024-06
  4. Efficacy and Safety of Tocilizumab in the Treatment of Generalized Myasthenia GravisRecruitingNCT05067348Study sitePhase 2Start 2022-07
  5. A Study of Nipocalimab Administered to Adults With Generalized Myasthenia GravisRecruitingNCT04951622Study sitePhase 3Start 2021-07
  6. Efficacy and Safety of Sugammadex in Thoracoscopy Thymectomy for Chinese Adults With Myasthenia GravisCompletedNCT06436768Lead sponsorN/AStart 2024-06

PubMed searchClinicalTrials.gov

Moyamoya disease

烟雾病
19.9%Leads about 1 in 5 of China's research papers on Moyamoya ▼ from 36.1%

Led 71 of 356 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (19.9%).

Run this PubMed search

Open trials led
9
Research papers it led
71
Trials it led
19
Share of China's trials
57.6%
Share of the world's papers
5.8%
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 1120242025: 332025
ThemesImaging & blood flowStroke & bleeding outcomesRevascularisation surgery

Hospitals counted here

  1. Beijing Tiantan Hospital60
  2. Xuanwu Hospital7
  3. Beijing Children's Hospital2
  4. Beijing Shijitan Hospital Counted in the group total1
  5. Fuxing Hospital Counted in the group total1
  6. Beijing Friendship Hospital Counted in the group total1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Remote ischemic conditioning prevents ischemic cerebrovascular events in children with moyamoya disease: a randomized controlled trial.2024World journal of pediatrics : WJPRCTFree full text
  2. Integrated analysis of the association between methionine cycle and risk of moyamoya disease.2023CNS neuroscience & therapeuticsRCTFree full text
  3. Choroid plexus enlargement correlates with cognitive dysfunction and disease progression in Moyamoya disease.2025Neurosurgical review
  4. Optimizing Surgical Timing to Reduce Stroke Risk in Pediatric Moyamoya Disease.2025Stroke
  5. Unraveling the Dyslipidemic Landscape in Moyamoya Disease: OxLDL as a Key Biomarker.2025CNS neuroscience & therapeuticsFree full text
Trials on ClinicalTrials.gov6
  1. Evaluating Antiplatelet and Physical Therapy for Slowing Progression in Mild Moyamoya Disease.Not yet recruitingNCT07762547Lead sponsorN/AStart 2026-07
  2. Development and Validation of Risk Prediction Models for Stroke and Cognitive Impairment in Moyamoya Disease and Moyamoya SyndromeRecruitingNCT07894107Lead sponsorStart 2026-08
  3. Efficacy and Safety of Ischemic Preconditioning Therapy Versus Optimal Medical Therapy in Reducing the Recurrence of Ischemic Events in Symptomatic Moyamoya DiseaseRecruitingNCT07889531Lead sponsorN/AStart 2026-10
  4. Study on the Mechanism of Cognitive Impairment in Patients with Moyamoya DiseaseRecruitingNCT06832839Lead sponsorStart 2024-12
  5. Study on Evaluating the Effectiveness of Statins in the Treatment of Moyamoya DiseaseRecruitingNCT06817434Lead sponsorStart 2024-12
  6. Family-Based Moyamoya Susceptibility and Early DetectionRecruitingNCT07517354Lead sponsorStart 2024-11

PubMed searchClinicalTrials.gov

Wilson disease

肝豆状核变性(Wilson 病)
7.5%Leads about 1 in 13 of China's research papers on Wilson disease ▲ from 5.2%

Led 15 of 201 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (7.5%).

Run this PubMed search

Open trials led
1
Research papers it led
15
Trials it led
1
Share of China's trials
6.2%
Share of the world's papers
2.2%
Papers led per year
2021: 0020212022: 2220222023: 0020232024: 2220242025: 002025
ThemesGenetics (ATP7B)Diagnosis & copper testsLiver disease & transplant

Hospitals counted here

  1. Beijing Youan Hospital, Capital Medical University5
  2. Beijing Friendship Hospital4
  3. Beijing Tongren Hospital3
  4. Beijing Chao-Yang Hospital Counted in the group total1
  5. Beijing Tiantan Hospital Counted in the group total1
  6. Beijing Anzhen Hospital Counted in the group total1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Biliary atresia

胆道闭锁
8.9%Leads about 1 in 11 of China's research papers on Biliary atresia

Led 19 of 214 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (9.8%).

Run this PubMed search

Open trials led
0
Research papers it led
19
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
2.5%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 332025
ThemesScreening & diagnosisLiver transplantComplications after surgery

Hospitals counted here

  1. Beijing Children's Hospital15
  2. Beijing Friendship Hospital4

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Anti-NMDA receptor encephalitis

抗 NMDA 受体脑炎
9.1%Leads about 1 in 11 of China's research papers on Anti-NMDA receptor encephalitis

Led 24 of 264 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (10.2%).

Run this PubMed search

Open trials led
2
Research papers it led
24
Trials it led
3
Share of China's trials
50.0%
Share of the world's papers
3.2%
Papers led per year
2021: 0020212022: 0020222023: 2220232024: 1120242025: 222025

Hospitals counted here

  1. Xuanwu Hospital9
  2. Beijing Tiantan Hospital6
  3. Beijing Tongren Hospital4
  4. Beijing Children's Hospital4

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Altered tyrosine metabolism and B lymphocyte profiles are associated with disease severity in pediatric anti-NMDAR encephalitis: a cross-sectional study.2025European journal of pediatrics
  2. Clinical and imaging features and treatment response of anti-NMDAR encephalitis combined with MOGAD.2025Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  3. Development of a short-term prognostic model for anti-N-methyl-D-aspartate receptor encephalitis in Chinese patients.2024BMC neurology
  4. Typical metabolic pattern of 18F-FDG PET in Anti-NMDAR encephalitis in the acute and subacute phases and its correlation with T2 FLAIR-MRI features.2023BMC neuroscience
  5. Factors influencing prognosis and relapse in patients with anti-N-methyl-D-aspartate receptor encephalitis.2023Multiple sclerosis and related disorders
Trials on ClinicalTrials.gov4
  1. Efgartigimod in Anti-NMDA Receptor Encephalitis.RecruitingNCT07822776Lead sponsorPhase 2Start 2026-06
  2. Efficacy and Safety of Taitacept in Treatment of Refractory or Recurrent Anti-NMDAR/anti-LGI1 EncephalitisRecruitingNCT06510283Lead sponsorPhase 2Start 2024-12
  3. Multicenter and Prospective Clinical Registry Study of Anti-N-methyl-D-aspartate Receptor Encephalitis in Beijing AreaStatus unknownNCT02443350Lead sponsorStart 2014-06
  4. A Study to Evaluate the Efficacy, Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Satralizumab in Participants With Anti-N-methyl-D-aspartic Acid Receptor (NMDAR) or Anti-leucine-rich Glioma-inactivated 1 (LGI1) EncephalitisActive, not recruitingNCT05503264Study sitePhase 3Start 2022-09

PubMed searchClinicalTrials.gov

Takayasu arteritis

大动脉炎
24.6%Leads about 1 in 4 of China's research papers on Takayasu arteritis ▲ from 15.3%

Led 46 of 187 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (24.6%).

Run this PubMed search

Open trials led
0
Research papers it led
46
Trials it led
1
Share of China's trials
4.0%
Share of the world's papers
5.7%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 552025

Hospitals counted here

  1. Beijing Anzhen Hospital23
  2. Capital Medical University Affiliated Anzhen Hospital7
  3. Xuanwu Hospital6
  4. Beijing Chao-Yang Hospital3
  5. Beijing Children's Hospital3
  6. Beijing Friendship Hospital2

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Acute left heart failure is the initial manifestation of Takayasu arteritis: a case report.2025BMC cardiovascular disorders
  2. Cerebral Perfusion Features in Takayasu Arteritis: Insights From pCASL MRI.2025International journal of rheumatic diseases
  3. Clinical characteristics and treatment of infantile Takayasu arteritis in the Chinese Han population: a single-center study.2025Pediatric rheumatology online journal
  4. The role of granulocyte colony-stimulating factor in Takayasu arteritis.2025Clinical rheumatology
  5. Clinical value of diagnosing ischaemic stroke in patients with Takayasu's arteritis combining multiple arterial occlusion and high-grade enhancement.2025Clinical and experimental rheumatology
Trials on ClinicalTrials.gov6
  1. A Registry Study on Biomarkers of Takayasu's Arteritis (ARSBTA)RecruitingNCT03372980Study siteStart 2016-01
  2. Remote Ischemic Conditioning for Cerebral Ischemia in Patients With Takayasu Arteritis (TARIC-1)Status unknownNCT06178419Lead sponsorN/AStart 2024-01
  3. Efficacy and Safety of Vunakizumab and Ivarmacitinib in the Treatment of Active Takayasu's ArteritisNot yet recruitingNCT07451665Study sitePhase 4Start 2026-04
  4. Comparison of Adalimumab and Tofacitinib in the Treatment of Active Takayasu ArteritisStatus unknownNCT05151848Study sitePhase 4Start 2022-01
  5. A Study to Evaluate the Efficacy and Safety of Upadacitinib in Participants With Takayasu Arteritis (TAK)Active, not recruitingNCT04161898Study sitePhase 3Start 2020-02
  6. Comparison of Mycophenolate Mofetil and Cyclophosphamide for Active Takayasu's ArteritisCompletedNCT03096275Study sitePhase 3Start 2017-03

PubMed searchClinicalTrials.gov

Idiopathic pulmonary fibrosis

特发性肺纤维化
2.4%Leads about 1 in 41 of China's research papers on Idiopathic pulmonary fibrosis ▼ from 6.4%

Led 24 of 989 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (4.3%).

Run this PubMed search

Open trials led
0
Research papers it led
24
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.6%
Papers led per year
2021: 0020212022: 0020222023: 3320232024: 2220242025: 002025
Papers it led5
  1. Identifying prothrombin and bone sialoprotein as potential drug targets for idiopathic pulmonary fibrosis.2024BMC pulmonary medicine
  2. Clinical manifestations and prognostic factors analysis of patients hospitalised with acute exacerbation of idiopathic pulmonary fibrosis and other interstitial lung diseases.2024BMJ open respiratory research
  3. MMP19 Variants in Familial and Sporadic Idiopathic Pulmonary Fibrosis.2023Lung
  4. Cluster features in fibrosing interstitial lung disease and associations with prognosis.2023BMC pulmonary medicine
  5. Newly diagnosed non-small cell lung cancer with interstitial lung abnormality: Prevalence, characteristics, and prognosis.2023Thoracic cancer
Trials on ClinicalTrials.gov6
  1. Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)RecruitingNCT07687459Study sitePhase 3Start 2026-09
  2. Menstrual Blood-Derived Mesenchymal Stem Cell Injection (SC01009) in the Treatment of Idiopathic Pulmonary FibrosisNot yet recruitingNCT07131150Study sitePhase 2Start 2025-08
  3. A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With NerandomilastActive, not recruitingNCT06238622Study sitePhase 3Start 2024-09
  4. A Study to Test Whether BI 1819479 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)CompletedNCT06335303Study sitePhase 2Start 2024-09
  5. Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis (IPF)CompletedNCT05938920Study sitePhase 2Start 2023-06
  6. A Study to Evaluate the Efficacy and Safety of Recombinant Human Pentraxin-2 (rhPTX-2; PRM-151) in Participants With Idiopathic Pulmonary FibrosisTerminatedNCT04552899Study sitePhase 3Start 2021-03

PubMed searchClinicalTrials.gov

Amyotrophic lateral sclerosis

肌萎缩侧索硬化症
1.5%Leads about 1 in 65 of China's research papers on Amyotrophic lateral sclerosis ▼ from 2.6%

Led 12 of 779 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (8.3%).

Run this PubMed search

Open trials led
0
Research papers it led
12
Trials it led
7
Share of China's trials
12.7%
Share of the world's papers
0.2%
Papers led per year
2021: 1120212022: 0020222023: 1120232024: 1120242025: 002025

Hospitals counted here

  1. Xuanwu Hospital7
  2. Beijing Tiantan Hospital4
  3. Beijing Children's Hospital1
  4. Beijing Chao-Yang Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Analysis of lncRNAs profiles associated with ferroptosis can predict prognosis and immune landscape and drug sensitivity in patients with clear cell renal cell carcinoma.2023Journal of biochemical and molecular toxicologyRCT
  2. The difference between cystatin C- and creatinine-based estimated glomerular filtration rate and survival in amyotrophic lateral sclerosis: a population-based cohort study.2026Neurodegenerative disease management
  3. Amyotrophic lateral sclerosis and myasthenia gravis overlaps syndrome: a series of case report.2024Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
  4. Unusual electrophysiological findings in a Chinese ALS 4 family with SETX-L389S mutation: a three-year follow-up.2021Journal of neurology
  5. Characterization of novel and recurrent SPTLC2 variants in childhood-onset amyotrophic lateral sclerosis: Insights into sphingolipid dysregulation.2026Journal of neuromuscular diseases
Trials on ClinicalTrials.gov6
  1. A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RAG-17 in Subjects With Amyotrophic Lateral Sclerosis (ALS) With Superoxide Dismutase Type 1 (SOD1) Gene MutationRecruitingNCT06556394Study sitePhase 1Start 2024-12
  2. hUC-MSC-sEV-001 Nasal Drops for Neurodegenerative DiseasesNot yet recruitingNCT06607900Lead sponsorPhase 1Start 2025-07
  3. Effects of L-Carnitine in Amyotrophic Lateral Sclerosis Patients With CHCHD10 MutationsCompletedNCT06849115Lead sponsorPhase 4Start 2024-07
  4. Tofacitinib in Patients With Amyotrophic Lateral SclerosisNot yet recruitingNCT06689982Lead sponsorEarly phase 1Start 2024-12
  5. Exploring Nasal Drop Therapy With Small Extracellular Vesicles for ALSStatus unknownNCT06598202Lead sponsorPhase 1/Phase 2Start 2024-12
  6. Safety and Tolerance of RAG-17 in Amyotrophic Lateral Sclerosis Patients With SOD1 Gene MutationCompletedNCT05903690Lead sponsorEarly phase 1Start 2023-05

PubMed searchClinicalTrials.gov

Duchenne muscular dystrophy

杜氏肌营养不良
1.4%Leads about 1 in 71 of China's research papers on Duchenne muscular dystrophy ▼ from 2.0%

Led 3 of 213 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (10.8%).

Run this PubMed search

Open trials led
0
Research papers it led
3
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.1%
Papers led per year
2021: 0020212022: 1120222023: 1120232024: 1120242025: 002025

Hospitals counted here

  1. Xuanwu Hospital1
  2. Beijing Children's Hospital1
  3. Beijing Tiantan Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Behçet disease

白塞病
2.5%Leads about 1 in 41 of China's research papers on Behçet disease ▼ from 5.7%

Led 6 of 245 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (22.9%).

Run this PubMed search

Open trials led
0
Research papers it led
6
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.5%
Papers led per year
2021: 0020212022: 0020222023: 2220232024: 1120242025: 222025

PubMed searchClinicalTrials.gov

Alport syndrome

Alport 综合征
3.5%Leads about 1 in 29 of China's research papers on Alport syndrome New since 2021

Led 2 of 58 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (17.2%).

Run this PubMed search

Open trials led
0
Research papers it led
2
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.6%
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 112025

Hospitals counted here

  1. Beijing Children's Hospital1
  2. Beijing Anzhen Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

IgA nephropathy

IgA 肾病
3.1%Leads about 1 in 32 of China's research papers on IgA nephropathy ▲ from 1.6%

Led 23 of 736 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (9.4%).

Run this PubMed search

Open trials led
0
Research papers it led
23
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
1.3%
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 2220242025: 222025

Hospitals counted here

  1. Beijing Children's Hospital7
  2. Beijing Hospital, Capital Medical University4
  3. Beijing Chao-Yang Hospital4
  4. Beijing Anzhen Hospital3
  5. Beijing Tongren Hospital2
  6. Xuanwu Hospital2

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Gaucher disease

戈谢病
6.7%Leads about 1 in 15 of China's research papers on Gaucher disease ▼ from 15.4%

Led 2 of 30 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (6.7%).

Run this PubMed search

Open trials led
0
Research papers it led
2
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.4%
Papers led per year
2021: 0020212022: 1120222023: 1120232024: 0020242025: 002025

Hospitals counted here

  1. Beijing Friendship Hospital2

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led2
  1. Global Epidemiology of Gaucher Disease: an Updated Systematic Review and Meta-analysis.2023Journal of pediatric hematology/oncology
  2. Update of treatment for Gaucher disease.2022European journal of pharmacology
Trials on ClinicalTrials.gov1
  1. A Study of Velaglucerase Alfa (VPRIV) in Chinese Children, Teenagers, and Adults With Type 1 Gaucher DiseaseCompletedNCT05529992Study sitePhase 3Start 2023-01

PubMed searchClinicalTrials.gov

Osteogenesis imperfecta

成骨不全症
7.1%Leads about 1 in 14 of China's research papers on Osteogenesis imperfecta ▲ from 3.1%

Led 7 of 99 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (17.2%).

Run this PubMed search

Open trials led
0
Research papers it led
7
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.9%
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 2220242025: 222025

Over half of these papers are lab or animal studies.

Hospitals counted here

  1. Beijing Stomatological Hospital5
  2. Beijing Jishuitan Hospital1
  3. Gynecology Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Primary biliary cholangitis

原发性胆汁性胆管炎
12.0%Leads about 1 in 8 of China's research papers on Primary biliary cholangitis ▲ from 8.7%

Led 36 of 300 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (12.0%).

Run this PubMed search

Open trials led
1
Research papers it led
36
Trials it led
2
Share of China's trials
4.0%
Share of the world's papers
3.6%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 442025
Papers it led5
  1. Noninvasive elastography-based assessment of liver fibrosis in primary biliary cholangitis.2026Annals of hepatology
  2. Real-world performance of transient elastography in assessing advanced fibrosis in Chinese patients with primary biliary cholangitis.2025World journal of gastroenterology
  3. GLOBE Score and UK-PBC Risk Score Predict Long-Term Clinical Outcomes of Patients With Primary Biliary Cholangitis and Receiving Ursodeoxycholic Acid and Fenofibrate.2025Journal of digestive diseases
  4. Clinicopathologic Features of a Rare and Underrecognized Variant of Early-stage Primary Biliary Cholangitis With Ductopenia.2025The American journal of surgical pathology
  5. Non-invasive assessment of esophageal and fundic varices in patients with primary biliary cholangitis.2025European radiology
Trials on ClinicalTrials.gov6
  1. PBC Long-term Outcomes StudyRecruitingNCT07149675Lead sponsorStart 2025-05
  2. A Study of CS0159 in Patients With PBC With Inadequate Response or Intolerance to UDCARecruitingNCT07282353Study sitePhase 3Start 2025-12
  3. Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated CirrhosisRecruitingNCT06051617Study sitePhase 3Start 2023-09
  4. Safety and Efficacy of Tauroursodeoxycholic Acid Versus Ursofalk in the Treatment of Adult Primary Biliary CirrhosisCompletedNCT01857284Lead sponsorPhase 3Start 2009-09
  5. Study on Clinical and Pathological Features of Primary Biliary Cholangitis and Risk Factors Related to Disease ProgressionNot yet recruitingNCT07733882Study siteStart 2026-08
  6. CS0159 in Chinese Patients With PBC (Primary Biliary Cholangitis)Active, not recruitingNCT05896124Study sitePhase 2Start 2023-08

PubMed searchClinicalTrials.gov

Primary sclerosing cholangitis

原发性硬化性胆管炎
7.0%Leads about 1 in 14 of China's research papers on Primary sclerosing cholangitis New since 2021

Led 7 of 100 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (7.0%).

Run this PubMed search

Open trials led
0
Research papers it led
7
Trials it led
1
Share of China's trials
16.7%
Share of the world's papers
0.7%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 2220242025: 222025

Hospitals counted here

  1. Beijing Friendship Hospital4
  2. Beijing Chao-Yang Hospital2
  3. Beijing Hospital, Capital Medical University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Congenital diaphragmatic hernia

先天性膈疝
5.0%Leads about 1 in 20 of China's research papers on Congenital diaphragmatic hernia New since 2021

Led 3 of 60 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (18.3%).

Run this PubMed search

Open trials led
0
Research papers it led
3
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.3%
Papers led per year
2021: 1120212022: 0020222023: 2220232024: 0020242025: 002025

Hospitals counted here

  1. Gynecology Hospital2
  2. Beijing Chao-Yang Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Hirschsprung disease

先天性巨结肠
9.3%Leads about 1 in 11 of China's research papers on Hirschsprung disease ▲ from 3.6%

Led 15 of 161 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (13.0%).

Run this PubMed search

Open trials led
0
Research papers it led
15
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
2.0%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 2220242025: 332025

Hospitals counted here

  1. Beijing Children's Hospital13
  2. Beijing Tongren Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Leber hereditary optic neuropathy

Leber 遗传性视神经病变
9.6%Leads about 1 in 10 of China's research papers on Leber hereditary optic neuropathy ▲ from 7.3%

Led 5 of 52 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (21.1%).

Run this PubMed search

Open trials led
0
Research papers it led
5
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
1.6%
Papers led per year
2021: 0020212022: 1120222023: 1120232024: 0020242025: 332025

Hospitals counted here

  1. Beijing Tongren Hospital4
  2. Beijing Tiantan Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov